How GLP‑1 Agonists Are Reshaping the Economics of Obesity Care
STEP-1 Trial Shows Semaglutide Cuts Weight by 15% - A Potential Health-Care Cost Saver In a landmark 68-week study, once-weekly semaglutide 2.4 mg lowered average body weight by 14.9% (p<0.001) versus placebo, equating to roughly 30 lb for a 200-lb adult. The trial also documented